Thymosin Alpha 1.
28-aa peptide that modulates T-cell function — used clinically in immune-compromised states.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Thymosin Alpha 1.
Thymosin Alpha 1 (Tα1, Zadaxin) is a 28-amino-acid acetylated peptide naturally produced in the thymus. It holds Marketing Authorisation in over 35 countries as adjunctive therapy for chronic hepatitis B and C, and is used as an immune adjuvant in oncology and post-infection contexts.
Tα1 has one of the largest evidence bases of any peptide in the longevity space, accumulated over decades of clinical use.
Tα1 activates pattern-recognition receptors (TLR9) on dendritic cells, driving T-cell differentiation toward Th1 responses and enhancing both natural killer cell activity and CD8+ T-cell maturation.
Subcutaneous injection, typically 1.6 mg twice weekly for 8–24 weeks depending on indication. Higher daily doses for acute interventions.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Garaci E, et al. — Thymosin alpha-1: from bench to bedside. Ann N Y Acad Sci · 2007 · doi: 10.1196/annals.1404.011
- INN / Name
- Thymosin Alpha 1
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.